Metastatic RCC Survival Approaching 5 Years
James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.
James Brugarolas, MD, PhD, director of the Kidney Cancer Program, professor of Internal Medicine, and the Sherry Wigley Crow Cancer Research Endowed Chair at the University of Texas Southwestern Medical Center, discusses updated survival data in patients with metastatic renal cell carcinoma (RCC).
According to Brugarolas, the prognosis of patients with metastatic RCC has significantly improved. This improvement has come in to 2 waves, the first with targeted therapies and the second with combination immunotherapy (IO) and tyrosine kinase inhibitors (TKIs). According to Brugarolas, the median survival of patients with metastatic RCC could be approaching 5 years.
0:08 | Well, so the prognosis of patients with metastatic RCC has improved significantly. The first improvement was with targeted therapies. Now the second wave was immunotherapies. And now with the combination of IO/TKI therapies. So, the most recent data we have is that patients nowadays, their median survival could be approaching five years, which is quite significantly improved compared to prior.
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Long-Term Data Prompt Shifting Approaches to Frontline RCC Therapy
October 8th 2024During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.
Read More
